Concepedia

Lawrence Chinn

LC

Statistics

Publications

7

Citations

524

H-Index

7

Active since

2005

Affiliations

Juvaris BioTherapeutics (United States)(Current)

Amgen (United States)

Lawrence Chinn is an author at Juvaris BioTherapeutics (United States) specializing in medicine, oncology, and molecular oncology.

Publications per year

2005–2015

7

Publications

7

Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

Christopher R. Behrens, Edward Ha, Lawrence Chinn et al. · Molecular Pharmaceutics · 2015 · 153 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

Metastatic properties and genomic amplification of the tyrosine kinase gene <i>ACK1</i>

Edward H. van der Horst, Yan Degenhardt, Astrid Strelow et al. · Proceedings of the National Academy of Sciences · 2005 · 145 citations · Full text

Medicine, Cancer Biology, Oncology +17

Antitumor activity of an anti‐<scp>CD</scp>98 antibody

Gregory M. Hayes, Lawrence Chinn, Joseph M. Cantor et al. · International Journal of Cancer · 2014 · 70 citations · Full text

Medicine, Oncology, Pharmacology +16

Discovery of Fully Human Anti-MET Monoclonal Antibodies with Antitumor Activity against Colon Cancer Tumor Models In Vivo

Edward H. van der Horst, Lawrence Chinn, Min Wang et al. · Neoplasia · 2009 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.

Gregory M. Hayes, Belinda Cairns, Zoia Levashova et al. · PubMed · 2015 · 42 citations

Medicine, Cancer Biology, Oncology +16

1–5 of 7